Does vaporised flower work faster than cannabis oil?

Generally, yes. Inhaled cannabinoids bypass the liver and absorb directly through the lung's extensive surface into the bloodstream, producing detectable plasma concentrations within minutes. Swallowed oils must pass through the gut and liver before reaching systemic circulation, which typically delays onset by 30 minutes to two hours. Sublingual oil falls somewhere between the two, though individual variation is significant.

Why does oral cannabis sometimes feel stronger or different to inhaled cannabis?

When THC passes through the liver during first-pass metabolism, it is partly converted to 11-hydroxy-THC — a metabolite that is itself psychoactive and crosses the blood-brain barrier readily. The presence of this metabolite, combined with the slower and more prolonged absorption profile of oral dosing, can produce a qualitatively different experience compared to inhalation, even at equivalent doses on paper.

What is the bioavailability difference between inhaled and oral cannabis?

Oral bioavailability of THC is generally reported in published pharmacology literature at roughly 4–20%, with wide variability between individuals. Inhaled bioavailability is considerably higher, though it too varies based on inhalation technique, device, and individual lung physiology. This is one reason the same nominal dose can produce very different effects depending on formulation and route.

Do cannabis oils contain terpenes?

It depends on the extraction process and formulation type. Full-spectrum oils aim to retain or reintroduce terpenes from the source plant. Broad-spectrum oils vary. Isolate-based products contain none. Terpenes are volatile and can be lost during extraction, so some manufacturers add them back post-processing — which raises open questions in the research literature about whether reintroduced terpenes behave identically to those naturally present.

Are vaporised flower and cannabis oil regulated differently in Australia?

No — the scheduling is determined by cannabinoid content rather than delivery format. THC-containing products are generally Schedule 8 controlled drugs under the Poisons Standard, regardless of whether they are dried flower or oil. CBD-dominant low-THC products may be Schedule 4. All legal medicinal cannabis products in Australia require either ARTG listing or access through the TGA's Special Access Scheme or Authorised Prescriber pathway.

Vaporised Flower vs Oil

By Tom Whitfield · 16 May 2026 · 8 min read

Scientist working in a vintage laboratory with glassware.

Vaporised flower vs oil: two routes, very different journeys

Roughly 1.3 million Australians held an active medicinal cannabis approval as of late 2024, according to TGA figures. A significant share of those patients are prescribed either a vaporised dried flower product or an oil-based formulation, sometimes both. Yet the pharmacological difference between the two is rarely explained in plain terms. That gap in the literature bothers me, professionally speaking.

The pharmacokinetics literature is the kind of reading that would put most people to sleep, but I find it genuinely absorbing, probably for the same reason I haul home cryptic-crossword books I never finish. The short version is this: the route of administration changes almost everything downstream.

Pharmacokinetics simply describes what the body does to a substance: how it is absorbed, distributed, metabolised and cleared. Two products can contain the same molecule and still produce very different concentration-time curves, because the route decides how fast the compound arrives and how much of it survives the trip. For a broader side-by-side, see routes of administration compared.

What actually happens when flower is vaporised

Dried cannabis flower contains cannabinoid acids, principally THCA and CBDA, that are pharmacologically distinct from their neutral counterparts. Heat converts them. Vaporisation at temperatures broadly between 170°C and 230°C drives decarboxylation, turning THCA into THC and CBDA into CBD within the aerosol before it ever reaches the lungs. If the chemistry is new to you, decarboxylation explained and cannabinoid acids vs neutral forms cover it step by step.

From there, absorption is fast. The alveolar surface area of the lung is enormous, somewhere in the range of 70 square metres in an adult, and cannabinoids cross into the pulmonary circulation without first passing through the liver. That matters enormously for bioavailability. Inhaled THC reaches detectable plasma concentrations within minutes. Peak levels typically occur before the person has finished a single session, depending on the device and inhalation technique.

Device and technique are real variables, not footnotes. Temperature setting, how the flower is prepared, and the way a person draws on the device all shift how much cannabinoid ends up in the aerosol. That is one reason inhalation data show wide spread between individuals, even when the product is identical.

The flower matrix also carries terpenes: volatile aromatic compounds including myrcene, limonene, beta-caryophyllene, linalool, and alpha-pinene, among others. These are largely lost or degraded in oil extraction processes unless specifically reintroduced. Whether their co-presence in the inhaled aerosol influences cannabinoid activity in humans, the so-called entourage effect, remains an active research question. The pre-clinical data is intriguing; the human evidence is thinner than advocates sometimes claim. The terpenes and entourage effect FAQ sets out where the argument stands.

Minor cannabinoids also travel along for the ride in whole flower: CBG, CBN, CBC, trace amounts of THCV and others, all present at concentrations that vary considerably between cultivars and batches. A full-spectrum product, by definition, preserves this range. Flower, when vaporised, is inherently full-spectrum, though that spectrum shifts with temperature, storage age, and how well the cultivar was grown and dried.

The oil pathway: first-pass metabolism and why it changes the numbers

Cannabis oils, whether suspended in a carrier oil and taken sublingually, or swallowed as a capsule, follow the gastrointestinal route. Swallowed oil goes straight through the gut wall and into the portal circulation, then the liver. That's first-pass metabolism, and it has significant consequences for THC in particular. The bioavailability and the first-pass effect article walks through the mechanism in more detail.

The liver converts THC to 11-hydroxy-THC, a metabolite that is itself psychoactive and, importantly, crosses the blood-brain barrier more readily than the parent compound. This is one pharmacological reason that oral cannabis onset is slower but the subjective experience can feel qualitatively different to inhaled cannabis, not just delayed, but different in character. Onset after swallowing an oil can range from 30 minutes to two hours depending on whether it's taken with food, the fat content of the carrier, gut motility, and individual variation in liver enzyme activity.

Sublingual administration, holding oil under the tongue, bypasses some of this. The mucous membranes of the floor of the mouth allow direct absorption into the systemic circulation, similar in principle to sublingual glyceryl trinitrate in cardiac medicine. In practice, though, most people swallow a portion of what they hold sublingually, so the pharmacokinetics end up mixed. Published studies on sublingual cannabis oils show high inter-individual variability in plasma concentrations, which is probably why patients report such different experiences on the same product and dose.

Overall oral bioavailability of THC is generally reported in the range of 4–20% in the pharmacology literature, a wide window, and considerably lower than inhalation. CBD oral bioavailability is similarly variable and low, partly because CBD is highly lipophilic and partly due to first-pass breakdown. Formulation matters here: nanoemulsified or lipid-based delivery systems can improve absorption, and this is an active area of product development in jurisdictions with more established regulatory frameworks. More on the numbers is in bioavailability of cannabinoids.

Oil formulation types and what they contain

Not all cannabis oils are equivalent, and the terminology can obscure meaningful differences. An isolate-based oil contains a single purified cannabinoid, usually CBD, dissolved in a carrier. A broad-spectrum oil carries multiple cannabinoids with THC substantially removed. A full-spectrum oil retains the cannabinoid and terpene profile of the source plant more completely. The article on full-spectrum vs broad-spectrum vs isolate unpacks the labels further.

Whether an oil is full-spectrum depends heavily on extraction method and post-processing. CO₂ extraction can preserve a wider terpene profile than some ethanol-based methods, but the specifics vary by manufacturer and aren't always transparent in patient-facing materials. Terpenes reintroduced post-extraction, rather than naturally retained, raise honest questions about whether they behave identically to those present in the original plant matrix. I'd argue the "full-spectrum" label on some oils does more marketing work than scientific work, though I accept the published data doesn't yet resolve this cleanly either way.

A practical habit for any reader is to ask what a label term is actually describing. "Full-spectrum" is not a standardised measurement; it is a descriptor, and two products carrying it can differ in which compounds are present and in what amounts. A certificate of analysis, where one is available, says more than the front of the bottle.

How these formulations interact with the endocannabinoid system

Both routes ultimately deliver cannabinoids to the same receptor populations. THC acts primarily as a partial agonist at CB1 receptors, which are distributed heavily in the central nervous system. CBD's pharmacology is considerably more complex: it has low affinity for CB1 and CB2 receptors directly but modulates endocannabinoid signalling through several other mechanisms, including inhibition of fatty acid amide hydrolase, the enzyme that breaks down anandamide.

The endocannabinoid system is the broader network these molecules interact with: a retrograde signalling system involving endogenous lipid mediators, their receptors, and the enzymes that synthesise and degrade them. Exogenous cannabinoids, whether arriving via the lung or the gut, engage this system, but their concentration-time profiles at the receptor level differ substantially depending on the route.

That difference has real implications for how researchers design clinical trials and how clinicians think about titration. An inhaled formulation with rapid onset and relatively short duration produces a pharmacokinetic profile that looks very different on a graph to an oral oil taken twice daily. Neither profile is inherently superior; they are different tools, with different kinetics, suited to different clinical contexts as determined by a prescribing physician.

Why the evidence type matters

Much of the mechanistic detail above comes from laboratory and animal work, and from small human pharmacokinetic studies. Those findings describe how a molecule behaves; they do not show that a given route produces a given outcome in patients. The distinction is spelled out in preclinical vs clinical research, and it is worth keeping in mind whenever a product page borrows a receptor diagram.

Regulatory context in Australia

Both vaporised flower and cannabis oils are Schedule 8 controlled drugs when they contain THC above threshold concentrations, regulated under the Schedule 8 provisions of the Poisons Standard. Lower-THC CBD-dominant products may be Schedule 4. All medicinal cannabis products legally available in Australia must either be listed on the ARTG or accessed through the TGA's Special Access Scheme or via an Authorised Prescriber pathway. Products must be manufactured to Good Manufacturing Practice standards.

The regulatory framework does not differentiate between formulation types in terms of access pathways; the scheduling is determined by cannabinoid content, not delivery format. Prescribing is a clinical decision made between patient and doctor, taking into account individual circumstances, medical history, and the evidence base for specific indications. The grouping of products is covered in medicinal cannabis product categories 1–5, and the regulator's role is outlined in the Therapeutic Goods Administration explained.

If you want to go deeper on how these molecules are classified and what the access pathways look like in practice, the TGA's published guidance is worth reading directly rather than through third-party summaries. The regulator's home page at tga.gov.au is the place to start.

Sources

Tom Whitfield, Health librarian, references & fact-checking

Common questions

Does vaporised flower work faster than cannabis oil?: Generally, yes. Inhaled cannabinoids bypass the liver and absorb directly through the lung's extensive surface into the bloodstream, producing detectable plasma concentrations within minutes. Swallowed oils must pass through the gut and liver before reaching systemic circulation, which typically delays onset by 30 minutes to two hours. Sublingual oil falls somewhere between the two, though individual variation is significant.
Why does oral cannabis sometimes feel stronger or different to inhaled cannabis?: When THC passes through the liver during first-pass metabolism, it is partly converted to 11-hydroxy-THC — a metabolite that is itself psychoactive and crosses the blood-brain barrier readily. The presence of this metabolite, combined with the slower and more prolonged absorption profile of oral dosing, can produce a qualitatively different experience compared to inhalation, even at equivalent doses on paper.
What is the bioavailability difference between inhaled and oral cannabis?: Oral bioavailability of THC is generally reported in published pharmacology literature at roughly 4–20%, with wide variability between individuals. Inhaled bioavailability is considerably higher, though it too varies based on inhalation technique, device, and individual lung physiology. This is one reason the same nominal dose can produce very different effects depending on formulation and route.
Do cannabis oils contain terpenes?: It depends on the extraction process and formulation type. Full-spectrum oils aim to retain or reintroduce terpenes from the source plant. Broad-spectrum oils vary. Isolate-based products contain none. Terpenes are volatile and can be lost during extraction, so some manufacturers add them back post-processing — which raises open questions in the research literature about whether reintroduced terpenes behave identically to those naturally present.
Are vaporised flower and cannabis oil regulated differently in Australia?: No — the scheduling is determined by cannabinoid content rather than delivery format. THC-containing products are generally Schedule 8 controlled drugs under the Poisons Standard, regardless of whether they are dried flower or oil. CBD-dominant low-THC products may be Schedule 4. All legal medicinal cannabis products in Australia require either ARTG listing or access through the TGA's Special Access Scheme or Authorised Prescriber pathway.